The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.

Monte Rosa’s MRT-8102 Phase 1 shows deep NEK7 degradation and strong hsCRP drops; plus $200M raise extends runway. Learn more about GLUE stock here.

The "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook 2026" report has been added to ResearchAndMarkets.com's offering. This report tracks developments currently taking place ...